Invention Grant
- Patent Title: Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
-
Application No.: US14651988Application Date: 2013-12-17
-
Publication No.: US09795561B2Publication Date: 2017-10-24
- Inventor: Christine Elaine Jones
- Applicant: Glaxo Group Limited
- Applicant Address: GB Brentford, Middlesex
- Assignee: Glaxo Group Limited
- Current Assignee: Glaxo Group Limited
- Current Assignee Address: GB Brentford, Middlesex
- Agent James P. Riek; R. Steve Thomas; William R. Majarian
- Priority: GB1222679.1 20121217
- International Application: PCT/EP2013/076978 WO 20131217
- International Announcement: WO2014/095924 WO 20140626
- Main IPC: A61K31/569
- IPC: A61K31/569 ; A61K47/26 ; A61K31/137 ; A61K31/439 ; A61K31/56 ; A61K9/00 ; A61J1/03
Abstract:
The present invention is directed to pharmaceutical combination products comprising a muscarinic acetylcholine receptor antagonist, fluticasone propionate and salmeterol xinafoate, and to their use in the treatment of inflammatory or respiratory tract diseases.
Public/Granted literature
Information query
IPC分类:
